GLP-1 Daily: Ozempic & Wegovy News
Compounded Tirzepatide Ads Face a Reality Check
Thursday, November 5, 2026 · 5 min
Good Life Meds faces an advertising watchdog’s recommendation to drop unsupported compounded tirzepatide claims, while Novo Nordisk accelerates its Wegovy pill rollout. Ask your prescriber what product-specific evidence and access options mean for your care.
Listen
Show notes
Good Life Meds faces an advertising watchdog’s recommendation to drop unsupported compounded tirzepatide claims, while Novo Nordisk accelerates its Wegovy pill rollout. Ask your prescriber what product-specific evidence and access options mean for your care.
In this episode
- National Advertising Division Recommends Good Life — GlobeNewswire
“In a challenge brought by Eli Lilly and Company, BBB National Programs’ National Advertising Division recommended that Good Life Meds, LLC discontinue the challenged express health benefit and personalization claims for its compounded Tirzepatide+ products and modify its…”
- Novo catches Wegovy pill tailwind in Q3 as CEO eyes new launch horizons in 2027 | Fierce Pharma — Fierce Pharma
“Beyond sales, which have been ticking up sequentially since Q2, patient volumes are moving back into positive territory, too. Following a “flat end to 2025” and a “slight decline” in Q1, Novo has subsequently added 1.2 million patients in the second quarter and now 1.2 million…”
- Camurus AB: Camurus initiates Phase 2b study of CAM2056 monthly semaglutide depot in obesity - Inderes — Inderes
“The Phase 2b study is expected to enroll 150 participants, randomized 1:1:1 to CAM2056 10 mg, CAM2056 20 mg, or placebo, administered every four weeks following an initiation period. The primary objective is to demonstrate superiority of CAM2056 20 mg over placebo in reducing…”